Early Specific Host Response Associated with Starting Effective Tuberculosis Treatment in an Infection Controlled Placebo Controlled Mouse Study

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  den Hertog, Alice L ^a   de Vos, Alex F ^b   Klatser, Paul R ^a   Anthony, Richard M ^a  

^a ROYAL TROPICAL INSTITUTE   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 17; INTERLEUKIN 6; ISONIAZID; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; FEMALE; IMMUNE RESPONSE; LUNG TUBERCULOSIS; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; STUDY DESIGN; TREATMENT RESPONSE;

ANIMALS; ANTITUBERCULAR AGENTS; CYTOKINES; FEMALE; HOST SPECIFICITY; ISONIAZID; METAGENOME; MICE; MICE, INBRED BALB C; PLACEBOS; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 84874568830     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057997     Document Type: Article

References (23)

1. Steingart KR, Henry M, Laal S, Hopewell PC, Ramsay A, et al. (2007) Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review. PLoS Med 4: e202.
2. Pai M, Menzies D, (2007) Interferon-gamma release assays: what is their role in the diagnosis of active tuberculosis? Clin Infect Dis 44 (1) (): 74-7.
3. Kunnath-Velayudhan S, Salamon H, Wang HY, Davidow AL, Molina DM, et al. (2010) Dynamic antibody responses to the Mycobacterium tuberculosis proteome. Proc Natl Acad Sci U S A 107: 14703-14708.
4. den Hertog AL, Mayboroda OA, Klatser PR, Anthony RM, (2011) Simple Rapid Near-Patient Diagnostics for Tuberculosis Remain Elusive-Is a 'Treat-to-Test' Strategy More Realistic? PLoS Pathog 7(11): e1002207.
5. Djoba Siawaya JF, Beyers N, van Helden P, Walzl G, (2009) Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis. Clin Exp Immunol 156(1): 69-77.
6. Riou C, Perez Peixoto B, Roberts L, Ronacher K, Walzl G, et al. (2012) Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis. PLoS One 7(5): e36886.
7. de Steenwinkel JE, de Knegt GJ, ten Kate MT, Verbrugh HA, Ottenhoff TH, et al. (2012) Dynamics of interferon-gamma release assay and cytokine profiles in blood and respiratory tract specimens from mice with tuberculosis and the effect of therapy. Eur J Clin Microbiol Infect Dis 31 (6) (): 1195-201.
8. Jindani A, Doré CJ, Mitchison DA, (2003) Bactericidal and sterilizing activities of anti-tuberculosis drugs during the first 14 days. Am J Respir Crit Care Med 167: 1348-1354.
9. Donald PR, Diacon AH, (2008) The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis (Edinb) 88 (Suppl 1): S75-83.
10. Mattos AM, Almeida Cde S, Franken KL, Alves CC, Abramo C, et al. (2010) Increased IgG1, IFN-gamma, TNF-alpha and IL-6 responses to Mycobacterium tuberculosis antigens in patients with tuberculosis are lower after chemotherapy. Int Immunol 22: 775-782.
11. Pokkali S, Das SD, (2009) Augmented chemokine levels and chemokine receptor expression on immune cells during pulmonary tuberculosis. Hum Immunol 70 (2) (): 110-5.
12. Smith SG, Lalor MK, Gorak-Stolinska P, Blitz R, Beveridge NE, et al. (2010) Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining. BMC Immunol 7 11: 35.
13. Hasan Z, Jamil B, Khan J, Ali R, Khan MA, et al. (2009) Relationship between circulating levels of IFN-gamma, IL-10, CXCL9 and CCL2 in pulmonary and extrapulmonary tuberculosis is dependent on disease severity. Scand J Immunol 69 (3) (): 259-67.
14. Rubbo PA, Nagot N, Le Moing V, Brabet M, Bourdin A, et al. (2012) Multicytokine detection improves latent tuberculosis diagnosis in health care workers. J Clin Microbiol 50 (5) (): 1711-7.
15. Ruhwald M, Bjerregaard-Andersen M, Rabna P, Eugen-Olsen J, Ravn P, (2009) IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay. BMC Res Notes 4 2: 19.
16. Lin Y, Gong J, Zhang M, Xue W, Barnes PF, (1998) Production of monocyte chemoattractant protein 1 in tuberculosis patients. Infect Immun 66 (5) (): 2319-22.
17. Juffermans NP, Verbon A, van Deventer SJ, van Deutekom H, Belisle JT, et al. (1999) Elevated chemokine concentrations in sera of human immunodeficiency virus (HIV)-seropositive and HIV-seronegative patients with tuberculosis: a possible role for mycobacterial lipoarabinomannan. Infect Immun 67 (8) (): 4295-7.
18. Torrado E, Cooper AM, (2010) IL-17 and Th17 cells in tuberculosis. Cytokine Growth Factor Rev 21 (6) (): 455-62.
19. Vesely JJ, Pien FD, Pien BC, (1998) Rifampin, a useful drug for nonmycobacterial infections. Pharmacotherapy 18 (2) (): 345-57.
20. Appelbaum PC, Spangler SK, Potter CR, Sattler FR, (1986) Reduction of oral flora with rifampin in healthy volunteers. Antimicrob Agents Chemother 29 (4) (): 576-8.
21. Bothamley GH, (2004) Epitope-specific antibody levels demonstrate recognition of new epitopes and changes in titer but not affinity during treatment of tuberculosis. Clin Diagn Lab Immunol 11 (5):: 942-51.
22. Tariq SM, Tariq S, (2004) Empirical treatment for tuberculosis: survey of cases treated over 2 years in a London area. J Pak Med Assoc 54 (2) (): 88-95.
23. Vassall A, van Kampen S, Sohn H, Michael JS, John KR, et al. (2011) Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness Analysis. PLoS Med 8 (11) (): e1001120.